Back to Search
Start Over
Longitudinal clinico-serological analysis of anti-nucleocapsid and anti-receptor binding domain of spike protein antibodies against SARS-CoV-2
- Source :
- International Journal of Infectious Diseases, Vol 112, Iss, Pp 103-110 (2021), International Journal of Infectious Diseases
- Publication Year :
- 2021
- Publisher :
- Elsevier, 2021.
-
Abstract
- Objectives Monitoring the antibody responses to SARS-CoV-2 infection and its correlation to clinical spectrum of disease is critical in understanding the disease progression and protection against re-infection. We assessed the nucleocapsid (N) and receptor-binding-domain of spike (SRBD) protein specific IgG and neutralizing antibody (NAb) responses in COVID-19 patients up to 8 months and its correlation with diverse disease spectrum. Methods During the first wave of the SARS-CoV-2 pandemic, from 284 COVID-19 patients, 608 samples were collected up to 8 months post infection. The patients were categorized as asymptomatic, symptomatic and severe. The N and SRBD IgG and NAb titers were evaluated and correlated with clinical data. Results A steep increase in antigen specific antibody titers was observed till 40 days post onset of the disease (POD), followed by a partial decline till 240 days. Severe disease was associated with a stronger SRBD IgG response and higher NAb titers. The persistence of antibody response was observed in 76% against N, 80% against SRBD and 80% for NAbs of cases up to 8 months POD. Conclusion RBD and N protein specific IgG persisted till 240 days POD which correlated with NAb response, irrespective of individual`s symptomatic status indicating overall robust protection against re-infection.
- Subjects :
- Microbiology (medical)
nucleocapsid
Disease
Infectious and parasitic diseases
RC109-216
Antibodies, Viral
Asymptomatic
Article
Serology
Persistence (computer science)
NLR
IgG antibody response
medicine
Humans
240 days
neutralizing antibody response
Neutralizing antibody
receptor binding domain
biology
business.industry
SARS-CoV-2
Antibody titer
COVID-19
General Medicine
Antibodies, Neutralizing
Titer
Infectious Diseases
Immunology
Spike Glycoprotein, Coronavirus
biology.protein
medicine.symptom
Antibody
business
Subjects
Details
- Language :
- English
- ISSN :
- 12019712
- Volume :
- 112
- Database :
- OpenAIRE
- Journal :
- International Journal of Infectious Diseases
- Accession number :
- edsair.doi.dedup.....871da227fabc055cbb378eb8d4804bd2